Cargando…

An evaluation of postmarketing reports of hyperglycaemia associated with dolutegravir for treatment of HIV in Eswatini

BACKGROUND: Dolutegravir (DTG) is an Integrase Strand Transfer Inhibitor (INSTI) indicated in combination with other antiretroviral agents for the treatment of HIV infection. It is available in a number of pharmaceutical preparations including the fixed-dose combination (TLD) containing tenofovir (3...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duga, Alemayehu L., Magongo, Sibongile, Nhlabatsi, Siphesihle, Ladwar, Denis O., Härmark, Linda, Rolfes, Leàn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694599/ https://www.ncbi.nlm.nih.gov/pubmed/36424607 http://dx.doi.org/10.1186/s12981-022-00481-0

Ejemplares similares

Postmarketing Surveillance of Pregnancy Outcomes With Dolutegravir Use
por: Crawford, Melissa, et al.
Publicado: (2020)

Strengthening the Evidence: Similar Rates of Neural Tube Defects Among Deliveries Regardless of Maternal HIV Status and Dolutegravir Exposure in Hospital Birth Surveillance in Eswatini
por: Gill, Michelle M, et al.
Publicado: (2023)

Assessment of early COVID-19 compliance to and challenges with public health and social prevention measures in the Kingdom of Eswatini, using an online survey
por: Padidar, Sara, et al.
Publicado: (2021)

Baseline assessment of pharmacovigilance activities in four sub-Saharan African countries: a perspective on tuberculosis
por: Tiemersma, Everdina W., et al.
Publicado: (2021)

Bayesian network-based spatial predictive modelling reveals COVID-19 transmission dynamics in Eswatini
por: Dlamini, Wisdom M. D., et al.
Publicado: (2021)

The Cascade of Care From Routine Point-of-Care HIV Testing at Birth: Results From an 18-Months Pilot Program in Eswatini
por: Khumalo, Philisiwe Ntombenhle, et al.
Publicado: (2020)

COVID-19 vaccine reactogenicity – A cohort event monitoring study in the Netherlands using patient reported outcomes
por: Rolfes, Leàn, et al.
Publicado: (2022)

Paediatric tuberculosis preventive treatment preferences among HIV-positive children, caregivers and healthcare providers in Eswatini: a discrete choice experiment
por: Hirsch-Moverman, Yael, et al.
Publicado: (2021)

Engagement in care among women and their infants lost to follow-up under Option B+ in eSwatini
por: Reidy, William, et al.
Publicado: (2019)

Patient feedback surveys among pregnant women in Eswatini to improve antenatal care retention
por: Teasdale, Chloe A., et al.
Publicado: (2021)

The role of dolutegravir in the management of HIV infection
por: Miller, Misty M, et al.
Publicado: (2015)

Enhanced Integration of TB Services in Reproductive Maternal Newborn and Child Health (RMNCH) Settings in Eswatini
por: Hartsough, Kieran, et al.
Publicado: (2022)

“The right time is just after birth”: acceptability of point-of-care birth testing in Eswatini: qualitative results from infant caregivers, health care workers, and policymakers
por: Sacks, Emma, et al.
Publicado: (2020)

Opportunities for improved HIV prevention and treatment through budget optimization in Eswatini
por: Minnery, Mark, et al.
Publicado: (2020)

Client and healthcare worker experiences with differentiated HIV treatment models in Eswatini
por: Reidy, William, et al.
Publicado: (2022)

Healthcare worker experiences with Option B+ for prevention of mother-to-child HIV transmission in eSwatini: findings from a two-year follow-up study
por: DiCarlo, Abby L., et al.
Publicado: (2019)

Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS
por: Taha, Huda, et al.
Publicado: (2015)

Dolutegravir/rilpivirine for the treatment of HIV-1 infection
por: Dowers, Ellen, et al.
Publicado: (2018)

Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? A case report
por: Mulindwa, Frank, et al.
Publicado: (2023)

Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV
por: Chapola, John C., et al.
Publicado: (2023)

Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? a case report
por: Mulindwa, Frank, et al.
Publicado: (2023)

Standard precautions for preventing Tuberculosis and HIV: Compliance of Eswatini university student nurses
por: Gina, Ncobile Sidzandza Victoria, et al.
Publicado: (2021)

Knowledge of final year undergraduate nursing students about HIV and AIDS in Eswatini
por: Dlamini, Makhosazana C., et al.
Publicado: (2022)

The economic burden of prostate cancer in Eswatini
por: Ngcamphalala, Cebisile, et al.
Publicado: (2022)

First case report of a perinatally HIV-infected infant with HIV resistance to dolutegravir associated with tenofovir/lamivudine/dolutegravir use in mothers
por: Francois, Kesner, et al.
Publicado: (2023)

156. Evaluating Antibiotic Use and Developing a Tool to Optimize Prescribing in a Pediatric HIV Clinic in Eswatini
por: Streatfield, Ashish E, et al.
Publicado: (2020)

Evaluating antibiotic use and developing a tool to optimize prescribing in a family-centered HIV clinic in Eswatini
por: Ness, Tara E., et al.
Publicado: (2021)

Evaluation of Community-Based, Mobile HIV-Care, Peer-Delivered Linkage Case Management in Manzini Region, Eswatini
por: Suraratdecha, Chutima, et al.
Publicado: (2022)

Evaluation of a Depression Intervention in People With HIV and/or TB in Eswatini Primary Care Facilities: Implications for Southern Africa
por: Putnis, Nina, et al.
Publicado: (2023)

An Evaluation of “Drug Ineffective” Postmarketing Reports in Drug Safety Surveillance
por: Misu, Takashi, et al.
Publicado: (2018)

HIV–1 resistance to dolutegravir: update and new insights
por: Wainberg, Mark A, et al.
Publicado: (2015)

Switch to dolutegravir is well tolerated in Thais with HIV infection
por: Goh, Orlanda Q, et al.
Publicado: (2019)

Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection
por: Zamora, Francis J, et al.
Publicado: (2019)

Dolutegravir Resistance in Malawi’s National HIV Treatment Program
por: van Oosterhout, Joep J, et al.
Publicado: (2022)

Low rates of prior HIV testing among HIV-positive adults accessing outpatient services in Eswatini
por: Nuwagaba-Biribonwoha, Harriet, et al.
Publicado: (2019)

940. Impact of Using Arts Programming to Support Treatment in Adolescents Living with HIV in Eswatini
por: Agrawal, Vedika, et al.
Publicado: (2020)

HIV incidence, viremia, and the national response in Eswatini: Two sequential population-based surveys
por: Nkambule, Rejoice, et al.
Publicado: (2021)

Factors associated with prognostic or treatment outcomes in HIV/AIDS patients with and without hypertension in Eswatini
por: Dlamini, Sabelo Bonginkosi, et al.
Publicado: (2021)

Detecting tuberculosis in pregnant and postpartum women in Eswatini
por: Pasipamire, Munyaradzi, et al.
Publicado: (2020)

Postmarketing pharmacovigilance: Remdesivir and cardiovascular events
por: Sullivan, John T.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ol1qvh3d2qmb11qbnj09fpg2a8